NEW YORK (GBI Research), 29 May 2012 - Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.
The new report* shows that while hospital hygiene campaigns to conquer MRSA encourage public awareness of the importance of antibacterials, academic researchers are struggling to secure interest from commercial giants who can push new discoveries through the clinical pipeline process.
One major issue currently threatening the antibacterials market is the development of drug resistance. Increasing use of antibacterials is leading bacteria to evolve over time and develop resistance to the drugs used to treat the conditions they cause. As antibiotic prescription increases, the rate of resistance is also seen to increase.
Escherichia coli, a major cause of urinary tract infections (UTIs), has become increasingly resistant to fluoroquinolones, while multi-drug resistant tuberculosis (MDR-TB) is on the rise as well.
Despite the rising unmet need caused by drug resistance, a lack of interest in developing the market is present, possibly due to recent slumps in drug prices and increased competition. Several popular branded antibacterial products have recently lost their patent exclusivity, or are expected to lose it soon. For example, the recent patent expiry of Johnson and Johnson’s blockbuster antibiotic Levaquin led to a dip in overall market revenue, as this drug is used in multiple indications. The high proportion of cheaper generic products has led to a reduction of the average annual cost of therapy and fragmented the market.
As a consequence, the therapy pipelines for the bacterial diseases outlined in GBI Research’s report are relatively weak. Many drugs are in development by academic institutions currently lacking the industrial backing to bring them to market. While alliances are forming between these institutions and pharmaceutical companies, this has a limited capacity to increase market revenues at the moment and investments remain unattractive for many branded drug manufacturers. However, the future may hold some developments for antibacterial research, with an increase in revenue predicted for 2013 following the market’s slow recovery from the patent expiry of Levaquin. The market is expected to generate annual revenues of $12.7 billion by 2017.
*Antibacterials Market to 2017 - Innovative Anti-infectives that Target MDR Gram-negative Pathogens Offer Significant Revenue Potential
This report provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe and Japan). It offers a comprehensive insight into antibacterial market based on the seven indications covered, and provides a disease overview for each indication, market forecasting, drivers and barriers, key marketed products, pipeline information and deals information for each disease in the top seven markets, as well as profiles for the main companies operating in the market.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com
